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Abstract
CD49d and CXCR4 are key determinants of interactions between chronic lymphocytic leukemia (CLL) tumor cells and their
microenvironment. In this study, we investigated the effect of CD49d and CXCR4 expressions on survival of CLL cells. Primary
CLL cells were cultured with CD49d ligand, VCAM-1, or bone marrow stromal cells (BMSCs); then, apoptosis and
immunophenotype analyses were performed. VCAM-1 treatment could not induce direct apoptosis protection or
immunophenotype change on the CD49d-expressing CLL cells, but resulted in actin reorganization. The BMSC-induced apo-
ptosis protection was independent from the presence of CD49d expression of CLL cells, but showed an inverse correlation with
their CXCR4 expression level. We suppose that CD49d contributes to enhanced survival of leukemic cells by mediating
migration to the protective microenvironment, not by direct prevention of apoptosis. Moreover, CLL cells with low CXCR4
expression represent a subpopulation that is more dependent on the microenvironmental stimuli for survival, and show increased
Bdeath by neglect^ when separated from the supportive niche.
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Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the
accumulation of mature CD5+ CD23+ B cells in the peripheral
blood, bone marrow, and secondary lymphoid tissues [1].
CLL cells receive several survival signals from the tumor
microenvironment, which are particularly important in CLL
progression and can contribute to therapy resistance [2].
In forming supportivemicroenvironmental interactions, the
CD49d adhesion molecule has crucial role. The CD49d is the
alpha4 integrin subunit, associated with the CD29 (beta1)
chain, which composes the very late antigen 4 (VLA-4;
CD49d/CD29) molecule. The CD49d is one of the strongest
poor prognostic factors in CLL and predicts shorter time to
treatment and overall survival at diagnosis [3–6]. The CD49d/
CD29 binds to fibronectin and VCAM-1, which is expressed
on endothelial cells and bone marrow stromal cells (BMSCs).
The involvement of CD49d in the survival of CLL cells has
already been reported in the literature, but its role in direct
apoptosis protection is ambiguous. CD49d+ CLL cells are
protected from spontaneous apoptosis due to adhesion to
VCAM-1 transfected fibroblast or VCAM-1 substrate [7, 8].
Interestingly, Brachtl and their colleagues found no impact of
CD49d/CD29-mediated adhesion on CLL cell viability [9].
The CD49d has an important role in leukocyte trafficking
and homing, which is a crucial process in the progression of
CLL [10, 11]. The CD49d/CD29 can be present in multiple
activation states, which determine the binding affinity to its
ligands and critical at effective homing [12]. Besides CD49d,
the other key component for recirculation of CLL cells is the
CXCR4 (CD184) chemokine receptor [13, 14]. CXCR4 act as
the receptor of CXCL12 chemokine secreted by BMSCs and
mediates chemotaxis and transendothelial migration [2, 15].
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The CXCR4 receptor is expressed at various levels on CLL
cells, which is influenced by the presence of CXCL12 and
BCR [15, 16]. Calissano et al. showed that CLL cells with
CD5high CXCR4dim phenotype have higher proliferation ac-
tivity [17], but the effect of different CXCR4 expressions on
the survival of CLL cells is unclear.
Our aim was to clear the role of different CD49d and
CXCR4 expressions on the survival of CLL cells by culturing
them onVCAM-1-coated plates or in co-culture with BMSCs.
According to our results, VCAM-1 does not directly provide
survival signals through the CD49d/CD29, but resulted in F-
actin formation in CLL cells with high CD49d expression.
BMSCs rescued CLL cells from apoptosis independently of
their CD49d expression. Furthermore, CXCR4low CLL cells
showed higher propensity to apoptosis than CXCR4high cells
that can be overcome by BMSCs.
These observations suggest that the CD49d has indirect
impact on viability via mediating migration and adhesion to
the protective lymphoid niches where tumor cells could get
survival signals from other molecules; furthermore, the ex-
pression of CXCR4 can indicate the dependency of CLL cells
on the signals from the microenvironment.
Materials and methods
CLL patients
Samples of 80 CLL patients (33 women and 47 men with
median age of 66 [43–83]) were obtained in the study. The
diagnosis of CLL was based on the World Health
Organization (WHO) classification of tumors of lymphoid
tissues [18]. The patients were not previously treated or had
not received treatment in the last 3 years. The study was con-
ducted in accordance with the Declaration of Helsinki and has
been approved by the local Ethics Committee in Semmelweis
University.
CLL cell purification and cell culture
Peripheral blood mononuclear cells (PBMCs) were isolated
by density gradient centrifugation over Ficoll-Histopaque
(Sigma-Aldrich, St. Louis, MO, USA). The ratio of the CLL
cells among the PBMCs was over 90% assessed by flow cy-
tometry. The isolated CLL cells were cultured at a concentra-
tion of 2 × 106 cells/ml in RPMI-1640 (Sigma-Aldrich) sup-
plemented with 10% fetal bovine serum (FBS; Sigma-
Aldrich), gentamycin (Sandoz, Boucherville, QC, Canada),
and L-glutamine (Gibco, Carbbad, CA, USA). The CLL cells
were cultured in medium alone, on VCAM-1-coated plates or
in co-culture with BMSCs. The BMSC cultures, isolated from
bone marrow aspirates of normal or ITP patients with no ab-
normal cells determined by flow cytometry, were prepared as
described previously [19]. BMSCs were cultured on 24-well
plates maintained at a concentration of 2 × 104 cells/ml in
Dulbecco’s modified Eagle’s medium (DMEM; Sigma-
Aldrich) supplemented with 20% FBS, gentamycin, and L-
glutamine. In co-culture experiments after discarding the
DMEM, 2 × 106 cells/ml CLL cells per well were seeded onto
the BMSC monolayer.
Coating plates and coverslips with VCAM-1
Wells of plates and plastic coverslips were coated with 10 μg/
ml recombinant human VCAM-1 (R&D Systems,
Minneapolis, USA) in bicarbonate buffer for 2 h at 37 °C or
for 4 °C overnight. After rinsing three times with phosphate-
buffered saline (PBS), non-specific binding sites were blocked
with 1% bovine serum albumin (BSA) in PBS for 2 h at 37 °C.
Followed by washing three times with PBS, CLL cells were
seeded onto the wells of the plate or onto the coverslips.
Immunophenotype of CLL cells by flow cytometry
CLL cells were stained with fluorochrome-conjugated mono-
clonal antibodies summarized in Supplemental Table 1. The
measurements were carried out with FACSCalibur (BD
Biosciences) and analyzed by CellQuest Pro software (BD
Biosciences). Twenty thousand events were acquired from ev-
ery sample. The instrument settings and fluorescence compen-
sations were regularly controlled by CaliBRITE beads; there-
fore, the settings are stable and the MFI values are comparable.
We used isotype controls (n = 3) to check the aspecific binding
under various culture conditions. Where positive and negative
separation was needed, we gated on lymphocytes, and the dou-
ble (e.g., CD19−/CD49d−)-negative population was used as an
internal control. In the case of other markers, we gated on
CD19-positive cells. Data were presented as geometric mean
of fluorescence intensity (MFI) or in percentage of positive
cells. After culturing, the immunophenotype was determined
by gating on living cells. Apoptotic cells were excluded accord-
ing to the lower FSC and higher SSC parameters. The cut-off
value between the CD49dhigh and CD49dlow samples was de-
termined at 30% of positive cells [4]. The two groups with
different CXCR4 expressions were based on the median value
of the geometric mean fluorescence intensity of CXCR4.
Analysis of apoptosis by Annexin V/PI staining
After 3 and 7 days of culturing, CLL cells were washed twice
with PBS then stained with 5 μl Annexin V-Alexa Fluor 647
(Biolegend) and propidium-iodide (PI) (1 mg/ml, Sigma-
Aldrich) according to the manufacturer’s instructions.
Samples were measured by flow cytometry. Living cells were
defined as Annexin V/PI-negative population.
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Confocal microscopy
105 isolated CLL cells were allowed to adhere to 10 μg/
ml VCAM-1 or 1% BSA (used as control)-coated cover-
slips for 30 min at 37 °C. After removing the non-
adherent cells, the cells were fixed with 4% paraformal-
dehyde for 10 min at 4 °C. Then, the coverslips were
washed with PBS three times, followed by permeabilizing
with 0.2% Triton-X for 5 min at room temperature.
Staining was performed by phalloidin-TRITC (Sigma-
Aldrich) for 30 min. After washing with PBS, coverslips
were placed to slides and visualized by confocal micros-
copy (Nikon TE 300 fluorescent microscope) then ana-
lyzed using ImageJ 1.48k program (NIH, Bethesda,
MD). Because of the great difference in adhesion rate
between CD49dhigh and CD49dlow CLL cells, we used a
Bgate^ by marking out the individual cells. In all samples,
the same gate was used. Randomly, at least 20 cells were
analyzed in every sample. In every analyzed cell, the area
occupied by phalloidin-positive reaction was determined,
expressed in percent. A threshold value was applied be-
cause of the background staining.
Statistical analysis
All variables were tested for normal distribution to select
the appropriate parametric or non-parametric statistical
procedure. Wilcoxon and Mann–Whitney U tests,
Spearman’s correlation coefficient, or by categorical vari-
ables chi-square test was used for statistical evaluation
using the SPSS statistical package version 20.0 (SPSS,
Chicago, IL, USA). Statistical significance was set at p
< 0.05.
Results
VCAM-1 does not prevent the apoptosis of CLL cells
First, the anti-apoptotic effect of VCAM-1 stimulation on
CD49dhigh and CD49dlow CLL cells was investigated. CLL
cells were cultured on VCAM-1-coated plate for 3 and 7 days
and the apoptosis rate was assessed by flow cytometry. Our
results show that VCAM-1 did not inhibit the spontaneous
apoptosis either in CD49dlow or in CD49dhigh CLL cases (per-
cent of living CLL cells in suspension vs. VCAM-1 after
7 days: CD49dlow group 37.8 ± 5.6 vs. 28.7 ± 15%;
CD49dhigh group 6.4 ± 1 vs. 5 ± 3.3%) (Fig. 1).
Tomodel the supportive niche of the bonemarrow, we used
isolated BMSCs in co-culture condition with neoplastic B
cells. The viability of the CLL cells was significantly higher
in co-culture with BMSCs compared to keeping them in me-
dium only (percent of viable CLL cells in suspension vs. with
stroma after 7 days: CD49dlow group 37.8 ± 5.6 vs. 62.5 ± 6%,
p = 0.028; CD49dhigh group 6.4 ± 1 vs. 25.3 ± 6%, p = 0.028).
The effect of BMSCs was more prominent after 7 days than
after 3 days; therefore, we used this culturing time period for
further experiments. There was no difference in BMSC-
induced pro-survival effect among CLL cells with different
CD49d expressions. In comparison with CD49dlow CLL cells,
the CD49dhigh CLL cells displayed increased sensitivity to
apoptosis in suspension and also in the presence of BMSCs
(p = 0.028; p = 0.046) (Fig. 1).
VCAM-1 engagement induces actin polymerization
in CD49dhigh CLL cells
Although VCAM-1 stimulation on its own was not sufficient
to exert anti-apoptotic effect on CLL cells, we tested the
Fig. 1 CLL cell viability in BMSCs co-culture or by VCAM-1 engage-
ment. CD49dhigh and CD49dlow CLL cells were cultured in medium
alone, with BMSCs or on VCAM-1 (10 μg/ml)-coated wells. After 3
and 7 days, cell viability was determined with Annexin V/PI staining,
measured by flow cytometry. The bar diagrams represent the mean
and SEM of 6 different cases from each CD49d group. Wilcoxon test
was performed for statistical evaluation. Statistical significance was
set at p < 0.05
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adhesive capacity of the cells towards the ligand, with actin
polymerization as a read-out. CLL cells with different CD49d
expressions were attached to VCAM-1-coated coverslips,
then were stained with phalloidin and analyzed by confocal
microscopy. We observed greater adhesion rate by CD49dhigh
CLL cells (data not shown); moreover, robust F-actin forma-
tion was detected as adhered to VCAM-1-coated slides com-
paring with control slides (% of phalloidin-positive area on
control vs. VCAM-1-coated slides 12.75 ± 0.85 vs. 27.45 ±
1.77%, p = 0.0001) (Fig. 2; Supplemental Fig. 1). CLL cells
with CD49dlow phenotype did not show significant difference
in actin reorganization after VCAM-1 contact (% of phalloidin
positive area on control vs. VCAM-1 coated slides 11.35 ±
0.79 vs. 12.01 ± 0.37%).
In contrast to VCAM-1, BMSCs modulate
the immunophenotype of CLL cells
Interaction with microenvironmental elements can change the
immunophenotype of CLL cells [19, 20]. We examined the
immunophenotype alteration of CD49dhigh and CD49dlow
CLL cells after VCAM-1 treatment or in BMSCs co-culture.
Markers involved in migration, activation, proliferation, and
co-stimulation (expression of CD49d, CD5, CD38, CD19,
CXCR4, CD126 (IL-6R α), CD80, and CD86) were analyzed
before and after 7 days of culturing in medium alone, on
VCAM-1 substrate, or together with BMSCs. VCAM-1 stim-
ulation alone did not change the immunophenotype of CLL
cells either in CD49dhigh or in CD49dlow cohort (data not
shown). In co-culture conditions with BMSCs, CLL cells
showed significantly elevated levels of CD5, CD49d, CD19,
and CD126 compared to CLL cells cultured in medium alone
(mean MFI of CD5 expression 158.5 ± 24.3 vs. 114.4 ± 17.8,
p = 0.002; of CD49d expression 93 ± 21.4 vs. 62.7 ± 15, p =
0.041; of CD19 expression 779.1 ± 95.8 vs. 531.4 ± 48.1, p =
0.002; of CD126 expression: 33.8 ± 4.2 vs. 30.4 ± 4.1, p =
0.020) (Fig. 3). Compared the two groups with different
CD49d levels, greater increase in CD5 expression was ob-
served after stromal cell contact by CD49dhigh CLL cells
(p = 0.03). Regarding the other surface markers, we did not
find any correlation with the CD49d level. BMSCs co-culture
did not result in significant changes in the expression of
CD38, CD80, and CD86 in our culture condition.
Furthermore, CXCR4 expression was decreased on CLL cells
in co-culture after 7 days (mean MFI of CXCR4 expression
124.1 ± 31.1 vs. 189.6 ± 40.7, p = 0.01). We checked the
aspecific binding under various conditions by using isotype
controls. We did not find significant changes in the fluores-
cence intensity of isotype controls in samples cultured in me-
dium or co-culturing with BMSCs.
CLL cells with low CXCR4 expression require greater
stroma-support, but show enhanced apoptosis rates
Analyzing the level of CXCR4 and CD49d positivity (and
CD49d MFI as well) (n = 80), an inverse correlation was ob-
served (p = 0.001) (Fig. 4a, Supplemental Fig. 2). Culturing
CLL cells with different CXCR4 expressions for 7 days in
medium, CXCR4low CLL cells showed greater rate of apopto-
sis compared with CXCR4high CLL samples (p = 0.03) (Fig.
4b). BMSCs increased the survival of CLL cells in both
CXCR4 group (percent of living cells after 7 days in
Fig. 2 Actin-polymerization of CD49dhigh and CD49dlow CLL cells upon
VCAM-1 stimulation. Primary CD49dhigh or CD49dlow CLL cells were
allowed to adhere to VCAM-1- or BSA-coated control coverslips for
30 min at 37 °C. After washing off the non-adherent cells with PBS,
the cells were fixed and permeabilized, then stained with phalloidin-
TRITC. Cells were visualized by confocal microscopy. As result, the area
occupied by phalloidin-positive reaction was given. Displayed results are
the mean and SEM of phalloidin-positive area by 3 different samples.
Wilcoxon test was performed for statistical evaluation. Statistical signif-
icance was set at p < 0.05
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suspension vs. in co-culture condition in CXCR4low group
11.1 ± 4.6 vs. 39.4 ± 8.7%, p = 0.018; in CXCR4high group
43.6 ± 9.9 vs. 51.8 ± 9.8%, p = 0.042) (Fig. 4b). The
CXCR4low CLL cells were more susceptible to apoptosis both
in medium and on BMSCs, but higher proportion of cells was
rescued in the co-culture with stromal cells compared with
CXCR4high cells (Fig. 4b). The increased survival of
CXCR4low CLL cells in the co-culture reveals a higher depen-
dence on BMSCs.
CXCR4 does not, but CD49d predicts poor prognosis
We have next investigated whether the microenvironmental
sensitivity is related to clinical parameters. It is well studied
that CD49dhigh CLL patients show advanced disease stage,
LDH level at diagnosis, and shorter time to treatment (TTT),
which was confirmed by our clinical data (Table 1) [3, 4, 21].
Interestingly, we observed lower absolute lymphocyte count
(ALC) at diagnosis by the CD49dhigh cases, but it did not
reach statistical significance (64.1 ± 12.6 vs. 77.6 ± 18 g/l).
Regarding the CXCR4 expression of CLL patients, no sig-
nificant difference was detected in any clinical parameters
between the CXCR4low and CXCR4high cohorts (Table 1).
Patients with Binet A stage represent a highly heterogeneous
disease group. Analyzing the Binet A CLL cases according to
the CXCR4 expression, significantly elevated LDH level was
found in the CXCR4low patient group (351.6 ± 39.2 vs. 206.4
± 21.8; p = 0.003).
Discussion
The main aim of this study was to analyze the effect of CD49d
and CXCR4 exp r e s s i o n s on t h e s u r v i v a l a nd
immunophenotype of CLL cells engaged by VCAM-1 or bred
under cond i t i ons tha t mimic the bone mar row
microenvironment.
Fig. 3 The surface molecule
expression of CD49dhigh and
CD49dlow CLL cells in BMSC
co-culture. Isolated CLL cells
from 12 different CLL blood
samples (6 from each CD49d
group) were cultured with
BMSCs or in medium alone
(suspension-control) for 7 days;
then, the expression of CD5,
CD49d, CD19, CD126, and
CXCR4 was analyzed by flow
cytometry gated on living cells.
The CD49dhigh cases were
displayed with gray; the
CD49dlow cases with black lines.
Wilcoxon tests were performed
for statistical evaluation.
Statistical significance was set at
p < 0.05
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The survival effect of CD49d has already been investigated
in CLL, but its role is proved to be controversial. We found
that the CD49d does not mediate survival signals by VCAM-1
stimulation. Furthermore, we detected that the anti-apoptotic
effect of BMSCs on CLL cells was independent of the CD49d
expression, although VCAM-1 is expressed on the stroma
surface [19]. Our findings are consistent with the results of
Brachtl et al. who used CD49d blocking antibody, which dis-
rupts the VCAM-1 binding but it did not alter the survival
rates of CLL cells [9]. In contrast, in the work of Zucchetto
et al., CLL cells were cultured with murine L-fibroblast
transfected with human VCAM-1 or VCAM-1 substrate alone
and found apoptosis protection, but this phenomenon was
observed after 7 days and was more prominent after 21 days
[7, 8]. Because of the big spontaneous apoptosis rates in our
experiments, we cultured the CLL cells at the longest for
7 days. The different culturing conditions might be an expla-
nation for the different results.
We studied whether the missing anti-apoptotic effect is the
result of impaired VLA-4 activation upon inside-out activa-
tion, e.g., by chemokine. However, we detected that at
unstimulated conditions, the CD49d/CD29 complex is
expressed in inactive, low-affinity confirmation on the surface
of CLL cells, but undergoes the normal activation process
after stimulation, e.g., VCAM-1 (Supplemental Fig. 3). Our
data are in agreement with previously published results, which
reported that the CD49d/CD29 is not in pre-activated form on
CLL cells [22].
We, however, did not detect any direct role of CD49d-
VCAM-1 binding in the survival of CLL cells. Our data
shows robust actin-remodeling in CD49dhigh CLL cells upon
VCAM-1 binding as was shown by Buchner et al. [23].
Therefore, CD49d may be important in several processes as-
sociated with cytoskeleton-remodeling, such as migration and
adhesion. More studies indicate higher homing rate to bone
marrow [9, 22, 24] and enhanced motility on VCAM-1 by
CD49dhigh CLL cells [25]. Additionally, our results show el-
evated CD49d level in the BMSCs co-culture, which mimic
the tissue microenvironment, similarly to other studies [19,
20]. CLL cells in the lymph node also have upregulated
CD49d expression [26]. Analyzing our clinical data, CD49d
high CLL patients have lower ALC at diagnosis, but it did not
reach statistical significance. The higher peripheral lympho-
cyte count can be explained by the greater migration and re-
tention in the lymphoid tissues by the CD49d-positive CLL
cells.
We confirmed that the ratio of CD49d-positive cells and the
level of CXCR4 show inverse correlation, similarly as de-
scribed by Ganghammer et al. [22]. High CD49d and weak
CXCR4 expressions are associated with clinical lymphade-
nopathy [27, 28]. We detected higher spontaneous apoptosis
rates by CD49dhigh CXCR4low CLL cells compared to
CD49dlow CXCR4high CLL cells. CLL cells are in continual
recirculation between the peripheral blood and lymphoid or-
gans. Malignant B cells, which encounter the tissue-derived
anti-apoptotic and growth signals in the microenvironment,
may be more susceptible to the lack of the favoring stimuli.
We suppose that this Bdeath by neglect^ effect can be resulted
in the observed big spontaneous apoptosis rate among
CD49dhigh CXCR4low CLL cells, which might represent a
recently emigrated population from the beneficial lymphoid
niches. Furthermore, our co-culture experiments showed in-
creased survival of CXCR4low CLL cells, indicating this pop-
ulation is more dependent on the microenvironmental stimuli.
The CXCR4 expression may reflect the microenvironmental
dependency, but it does not have prognostic impact at diagno-
sis according to our data, although in the heterogeneous Binet
Fig. 4 The correlation of CXCR4 level with CD49d positivity and the
spontaneous apoptosis rate of CLL cells with different CXCR4
expressions. a Correlation between the CXCR4 MFI and CD49d
positivity (expressed in %) on CLL cells. The expressions of CXCR4
and CD49d have been measured on freshly isolated CLL cells by flow
cytometry (n = 80). Correlation was evaluated with the Spearman
correlation coefficient. Significance was determined at p < 0.05. b CLL
cells with low CXCR4 level take greater advantage of BMSC-protective
effect after culturing for 7 days, though showed increased cell death. CLL
cells with low or high CXCR4 expression were cultured in medium alone
or in the presence of BMSCs. After 7 days, cell viability was determined
with Annexin V/PI staining, measured by flow cytometry. The bar dia-
grams represent the mean and SEM of 6 different cases from each groups.
Wilcoxon tests were performed for statistical evaluation. Statistical sig-
nificance was set at p < 0.05
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A patient group low CXCR4 expression was significantly
associated with elevated LDH level at diagnosis, which may
indicate high turnover rate of CLL cells. However, this can be
a result of the inverse correlation with CD49d expression,
which is reported to predict progressive disease in Binet A
CLL [21].
The characteristics of CLL cells are modulated by microen-
vironmental triggers contributing to enhanced survival and pro-
liferation. As our findings, VCAM-1 alone was not sufficient to
induce phenotypical changes, but BMSCs co-culture resulted
in higher CD49d, CD19, CD5, and CD126 and diminished
CXCR4 level as was shown in partly in our previous work
[29]. BMSC-derived antigens can stimulate BCR on CLL cells
[30], which may give rise to the increased CD19 and CD5
levels and the downregulation of CXCR4 [31]. However, the
diminished CXCR4 level could be also the effect of the
CXCL12 produced by BMSCs. The higher CD5 expression
may indicate the activation of malignant B cells, which was
more prominent in the CD49dhigh population. CLL cells ex-
press higher level of CD126 compared to normal B cells, which
is correlated with STAT-3 expression and chemoresistance
[32]. In our study, the CD126 level was increased on CLL cells
in the presence of BMSCs, which indicate its role in neoplastic
B cell-tumor microenvironment cross-talk and the
microenvironment-induced therapy resistance.
We showed in this study that VCAM-1 engagement by the
CD49d/CD29 did not prevent CLL cells from apoptosis or
induce immunophenotypical changes, but resulted in actin
remodeling. We suppose that the CD49d/CD29 complex
may contribute to enhanced survival of CLL cells by mediat-
ing migration and adhesion to the protective microenviron-
ment, not by direct inhibition of apoptosis. Furthermore,
CD49d-positive CLL cells express lower level of CXCR4
and represent a population being more dependent and sensi-
tive to the microenvironmental stimuli. These results suggest
to study and consider the expression of CXCR4 on CLL cells
which can predict the effect of a microenvironment-targeted
therapy. On the basis of our data, it may be reasonable to test
targeted therapies whether they have the capacity to mobilize
CD49dhigh/CXCR4low cells from the protective microenviron-
ment making them very susceptible to apoptosis in these poor
prognostic cases.
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